Trial Profile
Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis The Einstein-DVT Dose-finding Study. A Phase II Evaluation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2020
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Low molecular weight heparins; Low molecular weight heparins; Vitamin K antagonists
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms EINSTEIN-DVT-dose-finding
- Sponsors Bayer
- 08 May 2009 Additional lead trial centres identified as reported by as reported by Australian New Zealand Clinical Trials Registry record.
- 08 May 2009 New source identified and integrated (Australian New Zealand Clinical Trials Registry, record no.ACTRN12605000597695).
- 15 Sep 2008 Results were published in Blood.